Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer

Purpose: Epidermal growth factor receptor (EGFR) is considered a potential therapeutic target for anti-EGFR therapy in triple-negative breast cancer (TNBC). However, the frequency of gene mutation in TNBC is low and varies with ethnicity. This study aimed to investigate the incidence of gene mutation in TNBC.

Methods: EGFR protein expression was evaluated by immunohistochemistry in tissue microarrays of 493 TNBC cases using four different primary antibodies, which included mutation-specific antibodies. For cases with an immunoreactivity level ≥1+, we performed pyrosequencing analysis for gene mutation. A case was considered mutation-positive when its mutation frequency minus its limit of detection (LOD) was >10%. Cases with mutation frequency higher than LOD were assessed for gene mutation status using the Cobas assay and by peptide nucleic acid-mediated polymerase chain reaction (PNA-clamping).

Results: Among 493 TNBCs, 148 (30.0%) exhibited staining ≥1+ for EGFR, including 78 with 1+, 49 with 2+, and 21 with 3+. Positive EGFR expression (≥2+) was significantly associated with lymphovascular invasion (=0.010), but not with overall survival (=0.444) or disease-free survival (=0.388). None of the 493 TNBCs harbored an gene mutation. Among 148 cases with an EGFR staining result ≥1+, five (3.4%) showed mutation frequencies (4.4%-10.9%) higher than LOD (2.6%-4.3%) in exons 19 (L747_P753>Q) or 21 (L858R and L861Q) as determined by pyrosequencing. However, Cobas and PNA-clamping failed to detect the presence of gene mutation in these five cases.

Conclusion: No activating mutation of gene of clinical significance was observed in 148 TNBC cases using three commercially available methods. Thus, gene mutation appears to be an extremely rare event in patients with TNBC.